These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6302255)

  • 41. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice.
    Fraser-Smith EB; Eppstein DA; Marsh YV; Matthews TR
    Antimicrob Agents Chemother; 1984 May; 25(5):563-5. PubMed ID: 6610387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-herpesvirus activity of carbocyclic oxetanocin G in vitro.
    Nishiyama Y; Yamamoto N; Yamada Y; Daikoku T; Ichikawa Y; Takahashi K
    J Antibiot (Tokyo); 1989 Dec; 42(12):1854-9. PubMed ID: 2559911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tricyclic nucleoside analogues as antiherpes agents.
    Golankiewicz B; Ostrowski T
    Antiviral Res; 2006 Sep; 71(2-3):134-40. PubMed ID: 16780965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiherpes effects and pharmacokinetic properties of 9-(4-hydroxybutyl) guanine and the (R) and (S) enantiomers of 9-(3,4-dihydroxybutyl)guanine.
    Ericson AC; Larsson A; Aoki FY; Yisak WA; Johansson NG; Oberg B; Datema R
    Antimicrob Agents Chemother; 1985 May; 27(5):753-9. PubMed ID: 2990325
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
    Ashton WT; Meurer LC; Cantone CL; Field AK; Hannah J; Karkas JD; Liou R; Patel GF; Perry HC; Wagner AF
    J Med Chem; 1988 Dec; 31(12):2304-15. PubMed ID: 2848125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enzymatic phosphorylation of the antiherpetic agent 9-[(2,3-dihydroxy-1-propoxy)methyl]guanine.
    Karkas JD; Ashton WT; Canning LF; Liou R; Germershausen J; Bostedor R; Arison B; Field AK; Tolman RL
    J Med Chem; 1986 May; 29(5):842-8. PubMed ID: 3009816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BWB759U, an analogue of acyclovir, inhibits human cytomegalovirus in vitro.
    Tyms AS; Davis JM; Jeffries DJ; Meyers JD
    Lancet; 1984 Oct; 2(8408):924-5. PubMed ID: 6148640
    [No Abstract]   [Full Text] [Related]  

  • 48. Inhibition of human herpesviruses by combination of acyclovir and human leukocyte interferon.
    Levin MJ; Leary PL
    Infect Immun; 1981 Jun; 32(3):995-9. PubMed ID: 6166569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acyclovir.
    Appelboom TM; Flowers FP
    South Med J; 1983 Jul; 76(7):905-9. PubMed ID: 6306847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine.
    Neyts J; Jähne G; Andrei G; Snoeck R; Winkler I; De Clercq E
    Antimicrob Agents Chemother; 1995 Jan; 39(1):56-60. PubMed ID: 7695329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolution of therapy for cytomegalovirus infection.
    Verheyden JP
    Rev Infect Dis; 1988; 10 Suppl 3():S477-89. PubMed ID: 2847284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG).
    Ashton WT; Karkas JD; Field AK; Tolman RL
    Biochem Biophys Res Commun; 1982 Oct; 108(4):1716-21. PubMed ID: 6295389
    [No Abstract]   [Full Text] [Related]  

  • 53. History, pharmacokinetics, and pharmacology of acyclovir.
    King DH
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 2):176-9. PubMed ID: 2828440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative efficacy of three antiviral drugs in mice herpetic keratitis.
    Inoue Y; Ohashi Y; Shimomura Y; Manabe R; Yamada M; Ueda S; Kato S
    Jpn J Ophthalmol; 1989; 33(1):125-31. PubMed ID: 2543857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment of murine cytomegalovirus disease does not prevent latent virus infection.
    Katzenstein DA; Crane RT; Jordan MC
    J Lab Clin Med; 1986 Aug; 108(2):155-60. PubMed ID: 3016127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interactions between virus and antiviral compounds in the host cell.
    Harmenberg J
    Med Biol; 1984; 62(6):299-303. PubMed ID: 6099858
    [No Abstract]   [Full Text] [Related]  

  • 57. 5-(2-Chloroethyl)-2'-deoxyuridine: a potent and selective inhibitor of herpes viruses in vitro and in vivo.
    Rosenwirth B; Griengl H; Wanek E; De Clercq E
    Antiviral Res; 1985; Suppl 1():20-8. PubMed ID: 3002256
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparison of the modes of antiviral action of 2'-nor-deoxyguanosine and its cyclic phosphate, 2'-nor-cyclic GMP.
    Germershausen J; Bostedor R; Liou R; Field AK; Wagner AF; MacCoss M; Tolman RL; Karkas JD
    Antimicrob Agents Chemother; 1986 Jun; 29(6):1025-31. PubMed ID: 3015013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with alpha-interferon against herpes simplex virus type 2 in mice.
    Fraser-Smith EB; Eppstein DA; Marsh YV; Matthews TR
    Antimicrob Agents Chemother; 1984 Dec; 26(6):937-8. PubMed ID: 6335382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Reusser P; Cordonnier C; Einsele H; Engelhard D; Link D; Locasciulli A; Ljungman P
    Bone Marrow Transplant; 1996 May; 17(5):813-7. PubMed ID: 8733703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.